MetaCap

Haemonetics (HAE) vs Solventum (SOLV)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Haemonetics (HAE) has outperformed Solventum (SOLV) over the past year, gaining 52.5% versus a gain of 1.9%. Solventum is the larger company by market cap ($14.36 billion vs $5.47 billion), about 2.6 times the size. On valuation, Solventum trades at a lower forward P/E (11.2x vs 19.2x for Haemonetics).

Solventum converts more of its revenue into profit, with a net margin of 18.7% versus 7.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HAE+52.51%SOLV+1.93%
+66%+14%-38%
Nov 21, 20251 yearNov 20, 2026
HAE+40.79%SOLV+21.50%
+48%+0%-48%
Mar 25, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HAE versus SOLV key metrics
MetricHAESOLV
Share price$120.16$84.50
Market cap$5.47B$14.36B
1-day change-0.17%-1.52%
YTD return+49.92%+6.64%
1-year return+52.51%+1.93%
5-year return+131.43%—
P/E ratio (TTM)53.1794.94
Forward P/E19.1711.20
EPS (TTM)$2.26$0.89
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.33B$8.32B
Revenue growth (YoY)-1.97%+0.86%
Net income (latest FY)$97.31M$1.56B
Gross margin59.04%53.47%
Operating margin11.75%26.20%
Net margin7.29%18.69%
52-week high$132.00$94.16
52-week low$51.00$62.38
Distance from 52-week high-8.97%-10.26%
Analyst consensusbuybuy
Avg. price target upside+22.49%+16.43%
Average volume659.70K1.03M
Shares outstanding45.54M169.96M
Employees3,00920,584
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Solventum is about 2.6 times larger than Haemonetics by market value ($14.36B vs $5.47B).
  • HAE has outperformed SOLV by 50.6 percentage points over the past year.
  • Solventum trades at a higher earnings multiple (94.9x vs 53.2x trailing P/E).
  • Solventum is more profitable, keeping 18.7 cents of every revenue dollar as net income versus 7.3 cents for Haemonetics.

About Haemonetics

HAE stock →

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.

Health Care · Medical/Dental Instruments · 3,009 employees

About Solventum

SOLV stock →

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems.

Health Care · Medical/Dental Instruments · 20,584 employees

HAE vs SOLV FAQ

Which is bigger, Haemonetics or Solventum?

Solventum (SOLV) is larger, with a market capitalization of $14.36B compared with $5.47B for Haemonetics (HAE).

Which stock has performed better over the past year, HAE or SOLV?

HAE returned +52.51% over the past 12 months, compared with +1.93% for SOLV (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, HAE or SOLV?

HAE has the lower trailing P/E at 53.2, versus 94.9 for SOLV. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Haemonetics and Solventum in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons